October 18, 2018
GenSight Biologics reports positive 72-week data from REVERSE Phase III clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON)
Media
October 17, 2018
Nordic Nanovector ASA: Change of Date for Q3 2018 Results Presentation and Webcast
October 15, 2018
Nomination Committee appointed in respect of AGM 2019 in Oncopeptides
October 15, 2018
Targovax Reports Encouraging Disease-free Survival (DFS) Data From Tg01 Trial in Resected Pancreatic Cancer
October 12, 2018
GenSight Biologics to present REVERSE data with GS010 at the 2018 Annual Meeting of the American Academy of Ophthalmology
October 12, 2018
Oncopeptides to present at the Jefferies London Healthcare Conference on November 14th
October 12, 2018
Nordic Nanovector Presentations at the Annual Congress of the European Association of Nuclear Medicine (EANM)
October 11, 2018
Targovax Key Opinion Leader Symposium on Oncolytic Viruses in New York City today, 11 October, 2018
October 09, 2018
Rights issue in Vicore oversubscribed by 33 percent – The company receives SEK 82.4M
October 08, 2018
Altimmune Announces $25 million Registered Direct Offering